Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma |
| |
| Authors: | Arielle G Bensimon Umang Swami Allison Briggs Joshua Young Yuan Feng |
| |
| Institution: | 1. Analysis Group Inc., Boston, MA, USA;2. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA |
| |
| Abstract: | Abstract Objective Pembrolizumab/axitinib significantly prolonged overall survival (OS) and progression-free survival (PFS), and increased objective response rate versus sunitinib in the phase III trial KEYNOTE-426 among previously untreated patients with advanced renal cell carcinoma (RCC). This study assessed the cost-effectiveness of pembrolizumab/axitinib versus other first-line treatments of advanced RCC from a US public healthcare payer perspective. |
| |
| Keywords: | Renal cell carcinoma first-line therapy pembrolizumab axitinib cost-effectiveness partitioned survival model |
|
|
